Participated · Equity · Aug 2025

The Boost Society buys off‑plan buildings from developers and operates managed residences that rent rooms and studios to students (typically one‑year stays) and to young professionals for shorter terms, with rents that bundle services and activities. It currently manages 37 residences comprising nearly 10,000 beds and reports a secured business volume of €480M since January. The group has seven construction sites under way (three due for delivery in September) and specific projects ranging from a 372‑bed site in Bron to a 663‑bed mega‑residence in Villeneuve‑d'Ascq opening in 2027. The company aims to reach 20,000 beds in France by 2030 and is also pursuing growth in Spain, where it already has six residences and a site in construction at Valencia. The Boost Society is based in Levallois‑Perret and was launched in 2014.

Participated · Series A · Jul 2025

Chloris Geospatial provides science‑based forest carbon insights by combining satellite data, proprietary sensor fusion, and machine learning to measure vegetation and biomass dynamics back to 2000. Its platform delivers high‑integrity, timely data for every acre of forest to support corporate carbon accounting, project developers, and market standards. The company will use the new funding to accelerate product development and expand its commercial and technical teams. Chloris plans to deepen partnerships across the carbon value chain and expand operations with a new European hub to support regional growth. Clients include corporations monitoring forest‑risk supply chains, nature‑based solution developers, and carbon market standard setters. Chloris Geospatial develops forest carbon measurement and monitoring technology that leverages artificial intelligence and machine learning to generate forest carbon insights. Its platform tracks biomass dynamics—from deforestation and degradation to tree growth—at scales from field to continental. Customers and stakeholders include governments, companies, civil society organizations, indigenous peoples, and local communities seeking to understand impacts on forest carbon projects and supply chains. The company said it will use the new funding to support continued commercial growth. CEO Marco Albani leads the company, which is based in Boston, MA. Adam Gibbon, Natural Capital Lead at AXA IM Alts, joined Chloris’s board of directors. Chloris Geospatial measures natural capital from space and provides science-based forest carbon insights. Led by CEO Marco Albani, the company builds its product with Earth observation data and machine learning to reliably assess forest carbon dynamics, including forest growth and degradation. Its core offering uses satellite data to estimate forest carbon and track changes over time. The company plans to use the recent funding to advance sensor-fusion technology and equip customers with globally consistent estimates for 2000–2022. Chloris also intends to extend spatial coverage and grow customer support services with the funds.

Participated · Series A · May 2025

ReproNovo is a biopharmaceutical company focused on developing treatments for reproductive medicine and women’s health. Its lead clinical compound, RPN-001 (leflutrozole), is being developed to treat male infertility, while RPN-002 (nolasiban) is designed to manage adenomyosis and improve embryo implantation in ART. Both assets are Phase 2 ready. The company intends to use the Series A proceeds to advance a pipeline of multiple Phase 2 programs. ReproNovo is led by CEO Jean Marie Duvall, CSO & CMO Joan‑Carles Arce, MD, PhD, and CFO BingMei Hao. It maintains a primary development team in Copenhagen and an additional development site in Barcelona, with corporate base in Lausanne, Switzerland.

Participated · Series C · Apr 2025

Biolinq is a healthcare technology company developing precision intradermal biosensors to improve metabolic health. Its initial product is a wearable biosensor patch with an array of tiny electrochemical microsensors that measure glucose continuously just beneath the skin’s surface, providing real-time feedback via a color-changing indicator light on the upper forearm. The device is designed to combine glucose monitoring with activity and sleep information to support people with Type 2 diabetes not on insulin. Biolinq’s platform is positioned for future multi-analyte sensing capabilities and the company says it has spent the last decade developing the underlying technology. The company recently completed a US pivotal trial and submitted for regulatory review; its intradermal glucose sensor remains investigational and is not yet FDA cleared. A $100 million Series C will finance the company’s push from development toward commercial readiness as it pursues US regulatory approval; Biolinq is headquartered in San Diego. Biolinq develops a wearable patch that uses an array of tiny electrochemical microsensors placed in the intradermal space to measure glucose and relative activity from just beneath the skin surface. The device is designed for simplicity and user feedback, with an intuitive on-device display that notifies users when glucose is within or outside target ranges. Its sensor array is engineered for redundancy, reliability and multi-analyte capabilities without the use of introducer needles or bleeding. Biolinq describes the intradermal glucose sensor as investigational and not yet cleared or approved by the FDA. The company is headquartered in San Diego, CA. Proceeds from the completed financing will fund completion of a U.S. pivotal clinical trial this year and support a subsequent FDA submission. Biolinq is developing a wearable biosensor platform whose first product is a needle-free, intelligent continuous glucose sensor with a novel integrated display on the device. The device leverages semiconductor-industry innovation to miniaturize electrochemical sensors into a micro-array of miniature biosensors roughly 25 times smaller than conventional glucose sensors, enabling redundant measurements for reliability. Early feasibility studies demonstrated the microarray patch can track glucose continuously for up to seven days in people with diabetes. Biolinq’s approach includes multiplexed sensing capabilities and immediate biosensor feedback designed to simplify diabetes management and support future consumer health and wellness applications. The company is advancing clinical, regulatory, manufacturing and commercialization milestones to expand the sensing category. Financially, Biolinq completed a $100 million Series B financing, described as a record private capital raise in the continuous glucose monitoring space, with a broad syndicate of strategic and financial investors. Biolinq is developing a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes interstitial fluid to provide actionable health information. Its first commercial product aims to let people with diabetes continuously monitor blood glucose without the pain and hassle of traditional continuous glucose monitoring systems. The platform is wirelessly enabled and designed to simultaneously measure multiple biomarkers, enabling a pipeline of biomonitoring products. Biolinq plans to use new financing to support growth of its technology platform and to fund additional clinical studies. The company completed its first clinical study in 2018 and reports promising initial clinical results. Biolinq was founded in 2012 and is located in San Diego. Biolinq develops a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes biomarkers in interstitial fluid. Its wirelessly-enabled, nickel-sized biosensor patch is designed to continuously monitor multiple biomarkers and its first commercial product targets blood glucose monitoring without the pain and hassle of traditional CGM systems. The company emphasizes factory calibration (no finger sticks), low cost-of-goods, high manufacturing uniformity, and ease of use. Biolinq intends to leverage its novel manufacturing approach to increase access to CGM and simplify diabetes management. The platform’s ability to simultaneously measure multiple biomarkers supports plans to build a pipeline of additional biomonitoring products. Biolinq was founded in 2012 (as Electrozyme, LLC) and is located in San Diego.

Led · Series A · Jul 2024

Novocuff develops the Novocuff Cervical Control System (CCS), a medical device designed to stabilize and close the cervix to retain amniotic fluid and sustain cervical length with the goal of extending pregnancy. The company is focused on improving pregnancy outcomes and reducing preterm births caused by PPROM and cervical shortening. Novocuff says it aims to transform the standard of care and bring the device to global markets, including low- and middle-income countries. Proceeds from an oversubscribed $26 million Series A will fund team expansion, a U.S. multi-center pivotal clinical trial planned for early 2025, pursuit of marketing authorization, and early-stage commercialization. The company completed an initial $2 million seed round prior to the Series A and has added clinical hires Kathryn Wine (VP, Clinical Affairs) and Marissa VanDeVeer (Clinical Engineer). Novocuff frames its work against the global burden of preterm birth, citing WHO data that preterm complications caused roughly 1 million infant deaths in 2020.